[PDF][PDF] The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis …
JW Van der Heijden, R Oerlemans… - Clin Exp …, 2009 - clinexprheumatol.org
JW Van der Heijden, R Oerlemans, WF Lems, RJ Scheper, BA Dijkmans, G Jansen
Clin Exp Rheumatol, 2009•clinexprheumatol.orgObjective The proteasome is a multicatalytic proteinase complex regulating the intracellular
breakdown of many proteins, including those mediating the activation of pro-inflammatory
signaling pathways (eg NFκB), cell proliferation and survival. Conceptually, proteasome
inhibitors may therefore elicit potential anti-inflammatory properties by inhibiting these
processes and thereby impair the cellular release of pro-inflammatory cytokines such as
Tumor Necrosis Factor-α (TNF-α) in RA patients.
breakdown of many proteins, including those mediating the activation of pro-inflammatory
signaling pathways (eg NFκB), cell proliferation and survival. Conceptually, proteasome
inhibitors may therefore elicit potential anti-inflammatory properties by inhibiting these
processes and thereby impair the cellular release of pro-inflammatory cytokines such as
Tumor Necrosis Factor-α (TNF-α) in RA patients.
Objective
The proteasome is a multicatalytic proteinase complex regulating the intracellular breakdown of many proteins, including those mediating the activation of pro-inflammatory signaling pathways (eg NFκB), cell proliferation and survival. Conceptually, proteasome inhibitors may therefore elicit potential anti-inflammatory properties by inhibiting these processes and thereby impair the cellular release of pro-inflammatory cytokines such as Tumor Necrosis Factor-α (TNF-α) in RA patients.
clinexprheumatol.org